Your first 90 days
Your first 90 days on Enspryng for NMOSD
What happens before the first fill, the days that matter, the label's rules and who to call, from the label, the drugmaker's own program and one insurer's written rules.
Enspryng is the NMOSD treatment you can give yourself at home, once your neurologist has you trained. Getting there takes a few steps. Three screening tests, any needed vaccines and an insurance approval come first. Then 3 starting doses arrive 2 weeks apart, with liver blood tests along the way. This page lays out that stretch from the FDA label, Genentech's support program and one insurer's written rules.
What has to happen before the first bottle ships
Enspryng has no REMS, so the first shot waits on 3 screening tests, any needed vaccines, an insurance approval and a delivery from the pharmacy. These are the 7 things in the way, in order.
A hepatitis B blood test
The label requires hepatitis B screening before the first dose.
- Enspryng is not given to anyone with active hepatitis B. If a past infection or carrier status shows up, the label asks your neurologist to involve a liver specialist before and during treatment.FDA label
A tuberculosis check
The label asks your neurologist to check for active tuberculosis and test for a hidden (latent) infection.
- Enspryng is not given with active or untreated latent tuberculosis.
- An infectious disease specialist may weigh in on treating it first.FDA label
Liver blood tests
The label asks for liver enzyme (ALT and AST) and bilirubin tests before treatment starts.
- It advises caution about starting if ALT or AST is more than 1.5 times the upper limit of normal.FDA label
Vaccines ahead of time
The label asks for live vaccines at least 4 weeks before the first dose, and other vaccines at least 2 weeks before whenever possible.
- Live vaccines are not recommended during treatment.FDA label
Your other medicines and health history
The Medication Guide asks you to tell your healthcare provider about every medicine, any liver problems, any recent or planned vaccine and any contact with tuberculosis.FDA label
The ENSPRYNG Start Form
To enroll in ENSPRYNG Access Solutions, you and your doctor both fill out the ENSPRYNG Start Form.
- A Patient Navigator then explains your coverage and works with the doctor's office or specialty pharmacy to get your medicine.Patient Navigators
Training for the first shot
The label says the first injection is given with a qualified healthcare professional guiding you.
- Your neurologist decides whether you or a caregiver can inject at home after training.FDA label
The days that matter
Counted from the first shot, with screening and vaccine windows before it, starting doses on days 15 and 29, and a dose every 4 weeks from day 57. Type your first-dose date and the tiles become real dates you can add to your calendar.
The tiles below count days from a first dose. Enter the date of yours, or the date you expect, and each tile becomes a real date on your calendar.
The date stays on your device. It is not sent to Trial Friend or anyone else. The calendar file works with Apple, Google and Outlook calendars.Start Form and the coverage check
You and your doctor complete the ENSPRYNG Start Form, and a Patient Navigator reviews your insurance.
- No source sets how long this takes, because each insurer works on its own timeline.
Hepatitis B, tuberculosis and liver tests
All 3 come before the first dose.
- Results that need a liver or infectious disease specialist can add time before the first shot.
Last day for live vaccines
The label asks for live or live-attenuated vaccines at least 4 weeks before the first dose.
- Ask your neurologist which vaccines you still need.
Other vaccines, when possible
Non-live vaccines, such as some seasonal flu shots, should come at least 2 weeks before the first dose whenever possible, the label says.
Approval, then the first carton ships
Once the plan approves, the pharmacy ships the medicine.
- Your Patient Navigator works with the office and the pharmacy to get it to you.
First starting dose, 120mg
The first injection is given with a qualified healthcare professional guiding you.
- Take the carton out of the refrigerator 30 minutes before, and inject into the belly or thigh.
Injection reactions
In the NMOSD trials, 9% had an injection reaction on Enspryng against 8% on placebo.
- Most were mild to moderate and came within 24 hours, most often diarrhea or itching at the site.
Second starting dose, 120mg
Two weeks after the first.
- Before every dose, the label asks you to check with your healthcare professional if you think you have an infection.
Third starting dose, 120mg
The last of the 3 starting doses.
- After this one, doses come every 4 weeks.
Liver blood test, every 4 weeks
The label asks for ALT and AST every 4 weeks for the first 3 months.
- The label says to stop Enspryng if ALT or AST rises above 5 times normal, and sets rules for any restart.
Neutrophil count
The label asks for a white blood cell (neutrophil) count 4 to 8 weeks after starting, then at intervals your neurologist sets.
Liver blood test, number 2
First every-4-weeks dose, then a new carton each time
Each carton holds one 120mg syringe or autoinjector, so every dose needs its own carton from the pharmacy.
- Doses then come every 4 weeks for as long as your neurologist prescribes.
Steady levels
The label says the medicine reaches steady levels in the blood after the 8-week starting period.
Liver blood test, number 3
First every-4-weeks dose, number 2
Liver tests every 3 months
After the first 3 months, the label moves liver tests to every 3 months for one year, then as your neurologist decides.
The label, revision by revision
The FDA lists which sections changed in each revision of a label. These are the revisions the current Enspryng label records, dated by the FDA, with a plain note on what each one meant for a patient. Older references and handouts can lag these by months.
Label dated October 23, 2026, read on DailyMed. FDA label
- October 2026
The FDA added thyroid eye disease in adults as a second use. The NMOSD dose, tests and warnings did not change.FDA letter
- June 2026
The label's administration instructions were revised in June 2026. That version lists a 120mg autoinjector alongside the 120mg prefilled syringe.June 2026 label
- September 2022
The FDA approved adding the phone number for the NMOSD pregnancy registry to the label and the Medication Guide.FDA letter
- May 2021
The FDA approved corrections to the body weight data in the side effects section.FDA letter
- August 2020
The FDA approved Enspryng for adults with NMOSD who are AQP4 antibody positive. It was the first approval for the drug.FDA letter
How the label says to take it
The parts of the prescribing information and the patient leaflet that come up in the first 3 months, in plain words.
- Three starting doses, then every 4 weeks
The label gives 120mg at weeks 0, 2 and 4, then 120mg every 4 weeks.
- The NMOSD dose is the same for every adult and does not depend on weight.FDA label
- The first shot with a professional
The first injection is given with a qualified healthcare professional guiding you.
- After training, you or a caregiver may inject at home if your healthcare professional decides it is right.FDA label
- Before you inject
Take the carton out of the refrigerator and let the syringe or autoinjector sit outside the carton for 30 minutes.
- Do not warm it any other way.
- Use it within 5 minutes of taking off the cap.FDA label
- Where to inject
Inject into the belly or thigh, staying 2 inches (5cm) from the belly button.
- Each shot goes at least 1 inch (2.5cm) from the last one.
- Skip moles, scars and tender, bruised or red skin.FDA label
- Check the medicine first
The liquid should be clear and colorless to slightly yellow.
- Do not use it if it is cloudy, discolored or has particles, or if the syringe was dropped or damaged.FDA label
- Storage at home
Keep the carton in the refrigerator at 36°F to 46°F (2°C to 8°C), in its box to block light.
- Do not freeze or shake it.
- It can stay out at up to 86°F (30°C) for 8 days in total.FDA label
- If a dose is missed
The Medication Guide asks you to talk with your healthcare provider about restarting.
- The label's plan depends on how long it has been, and a gap of 8 weeks or more means restarting with extra starting doses.FDA label
- Infections can delay a dose
Before every dose, the label asks you to contact your healthcare professional if you suspect an infection, even a small one.
- The dose waits until the infection clears.FDA label
- Sharps disposal
Each syringe is used once.
- Put used syringes in a puncture-resistant sharps container, kept out of reach of children.FDA label
- Pregnancy and breastfeeding
It is not known whether Enspryng harms an unborn baby.
- A pregnancy registry for women with NMOSD takes calls at 1-833-277-9338.
- Ask your healthcare provider about feeding your baby, since passage into breast milk is unknown.FDA label
What the label says to act on
The symptoms the label singles out, and what it tells patients and prescribers to do about each. If any of these happen, the label's instruction is the one to follow, with your care team.
Signs of infection
Chills, tiredness, muscle aches, a cough that will not go away, sore throat, red or painful skin, diarrhea, belly pain, or burning when you urinate.
- The Medication Guide says to call your healthcare provider right away.FDA label
Signs of a serious allergic reaction
Trouble breathing, dizziness or fainting, swelling of the lips, face or tongue, bad stomach pain or vomiting, or chest pain.
- The Medication Guide says to get medical help right away.FDA label
Hives, rash or flushing after a shot
Tell your healthcare provider before your next dose.
- The label says a patient with signs of a serious allergic reaction should not take more doses until a healthcare professional checks them.FDA label
Liver enzymes and neutrophils
In the trial without other immune drugs, ALT rose above normal in 43% on Enspryng against 13% on placebo.
- Neutrophils fell below 1 x 10^9/L in 10% against 9%.
- These show up on blood tests, which is why the tests matter.FDA label
Common side effects
The most common in the NMOSD trials were sore throat and runny nose, headache, upper respiratory infection, stomach lining inflammation, rash, joint pain, arm or leg pain, tiredness and nausea.FDA label
Why the pharmacy or the insurer says no, and what fixes it
Most first-fill delays are one of these. Knowing which one tells you who to call.
- Prior authorization pending or deniedThe FEP policy below asks for age 18 or older and a positive AQP4 antibody test. It also asks for liver tests before starting and a plan to monitor liver enzymes and neutrophils. The neurologist's records usually answer what the plan is asking for.FEP Blue policy
- Screening results are missingHepatitis B, tuberculosis and liver test results are needed before the first dose. The policy also asks that there be no active hepatitis B and no active or untreated latent tuberculosis.FEP Blue policy
- Waiting on the insurance approvalGenentech's site for doctors describes free sample doses for practices that cover the first 2 months, the 3 starting doses and the first every-4-weeks dose. Ask your neurologist whether the office can use them.Genentech sample program
- The plan says no after reviewGenentech says a patient whose plan denied coverage, after any required prior authorization, can apply to the Genentech Patient Foundation. Proof of an appeal is not needed to apply.Genentech HCP FAQ
- A copay you cannot payCommercial insurance: the ENSPRYNG Co-pay Program, as little as $0 per 30-day supply, up to $20,000 a calendar year. Medicare, Medicare Advantage, Medicaid, VA, DoD and TRICARE are excluded. Our help paying page lists charity funds that may cover what remains.Genentech financial help
- Medicare, Medicaid or no insuranceThe co-pay program does not apply. Genentech points to independent foundations, which set their own rules. The Genentech Patient Foundation gives free Enspryng to eligible people, including uninsured people with incomes under $150,000.Genentech financial help
- The next carton has not shippedEach carton holds one dose, so each dose needs its own fill. Your Patient Navigator works with the doctor's office and specialty pharmacy, and takes calls at 1-844-677-7964 throughout your treatment.Patient Navigators
- The renewal after a yearThe FEP policy renews for 12 months at a time when your neurologist documents fewer relapses on Enspryng. Renewals allow 3 syringes every 84 days. Ask the office when the renewal is due.FEP Blue policy
Blue Cross Blue Shield Federal Employee Program prior authorization policy, April 1, 2026
- Age 18 or older
- Neuromyelitis optica spectrum disorder with a positive anti-aquaporin-4 (AQP4) antibody test
- AST, ALT and serum bilirubin checked before starting
- The prescriber agrees to monitor AST, ALT and neutrophil counts
- No active hepatitis B infection, and no active or untreated latent tuberculosis
- Not given at the same time as live vaccines
Approval length. Twelve months at first, up to 15 syringes. Renewals are 12 months at a time, up to 3 syringes every 84 days, when the patient has had fewer relapses on Enspryng.
This policy was approved on March 6, 2026 and cites a March 2022 label. It predates the June 2026 and October 2026 labels. The current label lists autoinjectors and adds a thyroid eye disease use. The NMOSD dose, tests and monitoring it describes match the current label. It is here as an example of what a plan asks for, not as a rule. FEP Blue policy
Who to call, and what they can do
The drugmaker's program handles most of the first-fill problems above. Charity funds and foundation help are on the help paying page.
- A Patient Navigator who explains your coverage, helps with the co-pay program and works with the doctor's office or specialty pharmacy to get your medicine
- The ENSPRYNG Co-pay Program, as little as $0 per 30-day supply for eligible commercial insurance, up to $20,000 a calendar year
- Co-pay help is not open to Medicare, Medicare Advantage, Medigap, Medicaid, VA, DoD, TRICARE or other government coverage, under the program's terms
- The Genentech Patient Foundation, free Enspryng for eligible people who are uninsured, whose plan does not cover it, or whose costs are high for their income. Foundation Specialists answer at 888-941-3331
- Referrals to independent co-pay foundations, which set their own rules and which people with Medicare or Medicaid can also contact
- Clinical Education Managers, Genentech employees who offer free extra injection training in the first year, after your doctor has trained and approved you
Details as the drugmaker publishes them. Genentech financial help
Five questions for the pharmacist or the support line
- Are my hepatitis B, tuberculosis and liver test results on file with the office?
- Which vaccines do I still need, and is there time for live vaccines 4 weeks before my first dose?
- Where will I get my first shot, and who will guide me through it?
- When will my next carton ship, and how do I keep it cold on the way?
- Has the co-pay program been applied to this fill?
- When are my liver and neutrophil blood tests due, and who orders them?
Questions people ask in the first weeks
How long does it take to start Enspryng after it is prescribed?
There is no fixed number of days. Three screening tests, vaccine windows, the Start Form, prior authorization and the pharmacy delivery each take their own time. Your Patient Navigator can help track where things stand.
How often is Enspryng given for NMOSD?
Every 4 weeks after 3 starting doses. The label gives 120mg at weeks 0, 2 and 4, then 120mg every 4 weeks, as a shot under the skin.
What tests do I need before my first Enspryng shot?
The label requires hepatitis B screening, a check for active and latent tuberculosis, and liver enzyme and bilirubin tests. Enspryng is not given with active hepatitis B or active or untreated latent tuberculosis.
Do I need vaccines before starting Enspryng?
The label asks for live vaccines at least 4 weeks before the first dose, and other vaccines at least 2 weeks before whenever possible. Live vaccines are not recommended during treatment.
How often will I need blood tests on Enspryng?
The label asks for liver enzyme tests every 4 weeks for the first 3 months, then every 3 months for one year. A neutrophil count is due 4 to 8 weeks after starting, then at intervals your neurologist sets.
Can I give Enspryng to myself at home?
Yes, if your healthcare professional decides it is right and you have been trained. The first injection is given with a qualified healthcare professional guiding you.
Is Enspryng approved if I do not have AQP4 antibodies?
No. The NMOSD approval covers adults who are AQP4 antibody positive. The label says there was no evidence of benefit in the antibody negative patients in either trial.
Is Enspryng used for other conditions?
Yes, the FDA added thyroid eye disease in adults in October 2026, with a dose based on body weight. This page covers only NMOSD.
Free email alert
Hear when the Enspryng label changes
One email the day the FDA revises the Enspryng label, with what changed in plain words. No trial alerts, no newsletter.
Label changes for Enspryng only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Want the whole condition instead? Follow Neuromyelitis optica spectrum disorder (NMOSD) for new trials, FDA decisions and label changes for every treatment.
Sources
- DailyMed - ENSPRYNG- satralizumab injection, solution (prescribing information revised October 2026, SPL version 16, Medication Guide and Instructions for Use), Genentech, via DailyMed, October 23, 2026.
- openFDA drug label record for ENSPRYNG, set ID 64c156a4-9bad-4d45-a294-0733c141f47b, SPL version 15, effective June 22, 2026, FDA, openFDA, June 22, 2026.
- Financial Assistance Options | ENSPRYNG (satralizumab), Genentech, November 8, 2026.
- Apply for Financial Support | ENSPRYNG (satralizumab), Genentech, November 8, 2026.
- Clinical Education Managers | ENSPRYNG® (satralizumab), Genentech, November 8, 2026.
- Treatment Schedule | ENSPRYNG® (satralizumab), Genentech, November 8, 2026.
- Financial Support FAQs | ENSPRYNG (satralizumab), Genentech, November 8, 2026.
- Genentech: Apply for Help, Genentech, November 8, 2026.
- Quick Start with ENSPRYNG® (satralizumab), Genentech, November 8, 2026.
- Eligibility and Enrollment | ENSPRYNG (satralizumab), Genentech, November 8, 2026.
- Pharmacy Policy 5.99.019, Enspryng, Blue Cross Blue Shield Federal Employee Program, April 1, 2026.
- BLA 761149/S-008 supplement approval letter, thyroid eye disease, FDA, October 15, 2026.
- BLA 761149/S-5 supplement approval letter, pregnancy safety study contact information, FDA, September 14, 2022.
- BLA 761149/S-2 supplement approval letter, body weight data corrections, FDA, May 3, 2021.
- BLA 761149 approval letter, Enspryng (satralizumab-mwge) injection for NMOSD, FDA, August 14, 2020.
This page explains what the FDA label, the drugmaker's support program and an insurer policy say. It is not medical advice and does not tell anyone to start, stop or change a medicine. Dosing, test timing and restarts after a gap are decisions for the prescribing neurologist. Found an error? Use the report link in the footer and it will be checked against the source.